Close

Ependymomas

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Overview

Ependymoma is a type of primary tumor which arises from the brain and the spine of central nervous system. It can occur in children and adults. Often, the location of ependymoma in children is intracranial, whereas in adults it is commonly diagnosed in spinal. The intracranial ependymoma always occurs in the fourth ventricle but rarely in the pelvic cavity. Once these tumors grow and fill the ventricle, they will block the flow of cerebrospinal fluid (CSF) through the brain and subsequently lead to the increased intracranial pressure.

Symptoms

The symptoms of ependymoma include severe headache, visual loss (caused by papilledema), vomiting, bilateral Babinski sign, drowsiness (following several hours of the above symptoms), gait change (rotation of feet when walking), impaction/constipation, back flexibility, neck pain, irritability, rapid and jerky eye movements and seizures. Moreover, symptoms of an ependymoma depend on the location and the size of the tumor.

Loading...
Products
Global Services
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.